Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin in COVID-19
NCT04392713Unknown
- Sponsor
- Combined Military Hospital
- Start
- Apr 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of CHILD-IVITAB in coronavirus disease 2019 (COVID-19), sponsored by Combined Military Hospital. Primary endpoint: Negative PCR at 144 hours. Status: unknown.
02
Drugs
CHILD-IVITAB
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04392713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392713.